We examined the effects of angiotensin II (Ang II) on inward rectifier K + currents (I K1) in rat atrial myocytes. 
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Introduction
The inward rectifier K + current ( I K1 ) is responsible for both terminal repolarization of the action potential and maintenance of the resting potential in excitable and nonexcitable cells ( 1 ) . Perturbation of this current may be involved in arrhythmogenesis in disease conditions such as coronary heart diseases ( 2 ) or dilated cardiomyopathy ( 3 ) . This arrhythmogenesis plays the pivotal role for atrial arrythmias, since the mutation of Kir2.1 encoding I K1 has been reported to cause the inherited atrial fibrillation ( 4 ) .
The potent vasoconstrictor angiotensin II (Ang II) can modulate various cardiac membrane currents, and its effects on I K1 have been examined in previous studies with contradictory results. For example, Ang II did not modulate I K1 in rat atrial myocytes ( 5 ) , whereas it inhibited the same current in porcine endothelial cells and mouse renal juxtaglomerular cells ( 6 , 7 ) . Still another report described stimulatory effects of Ang II on I K1 in rabbit ventricular myocytes ( 8 ) . Ang II binds to type 1 (AT 1 ) and type 2 (AT 2 ) receptors. Each of these receptor subtypes is coupled with a subset of G proteins which activates various signaling pathways, including the conventional phospholipase C/Ca 2+ /protein kinase C (PLC/ Ca 2+ /PKC) and adenylate cyclase/cAMP/protein kinase A (AC/cAMP/PKA) signaling pathways. Since I K1 is regulated by both PKC and PKA ( 9 , 10 ) , it is reasonable to assume that selective activation of signaling pathways in a given cell type may underlie the differential effects of Ang II.
It appears, however, that the selective activation of signaling pathways is not the sole determinant of cells' responses, because it has been shown that I K1 can be modulated in opposite ways in response to the activation of the same signaling pathway. For example, PKA activation increased I K1 through Kir2.1 expressed in Xenopus oocytes ( 9 ) , whereas it decreased I K1 through endogenous channels in guinea pig ventricular myocytes ( 11 ) . Kir channels are composed of heterogeneous subunits ( 10 ) , and it is likely that the molecular nature of the channel proteins in a given cell type is a basis for the differential effects of Ang II.
Although the atria have a higher binding capacity for Ang II than do ventricles in the guinea pig heart ( 12 ), there is limited information on the effects of Ang II on atrial I K1 (13, 14) . The initial purpose of the current study was to determine whether Ang II influences rat atrial IK1. Following confirmation of the inhibitory effects of Ang II, we attempted to determine the receptor subtypes and signaling pathways responsible for the effects. Given the altered characteristics of IK1 in spontaneously hypertensive rats (SHR) (15), we also examined the effects of Ang II on IK1 in SHR atrial myocytes.
Methods

Cell Isolation
Eight week-old Wistar-Kyoto (WKY) rats (16) (systolic blood pressure= 140±8 mmHg, mean±SEM; n=8) or SHR (175±7 mmHg, n=8) weighing 120-180 g were anesthetized with pentobarbital and the hearts were quickly isolated. Atrial myocytes were enzymatically isolated as described previously (17) . Cells were dispersed in the recording bath and superfused with Tyrode's solution containing (in mmol/l) 140 NaCl, 5.4 KCl, 0.5 MgCl2, 1.8 CaCl2, 5 HEPES and 5.5 glucose (pH 7.4).
All procedures were performed in accordance with the Tottori University Animal Care Guidelines, which conform to the NIH Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1985) .
Membrane Preparations and [ 125 I]-SarIle-Ang IIBinding Assays
Membrane preparations were obtained from pooled atrium samples as described previously (18) . They were incubated with increasing concentrations (0.05-1 nmol/l) of [
125 I]-SarIle-Ang II for 2 h at 20°C in buffer containing (in mmol/l) 50 Tris-HCl, 100 NaCl, 10 MgCl2, and 1 EDTA, supplemented with 0.25 mg/ml BSA and 10 mg/ml bacitracin (pH 7.6). Bound and unbound ligands were separated by rapid absorptive filtration (19) . Specific binding was defined as the difference between binding capacities in the absence and presence of excess Ang II (10 μmol/l). Dissociation constant (Kd) and maximum binding capacity (Bmax) values were estimated by Scatchard analysis of the saturation data. For inhibition isotherms, membrane preparations were incubated with 10 nmol/l [ 125 I]-SarIle-Ang II and increasing concentrations of the AT1 antagonist losartan or the AT2 antagonist CGP42112A (Fig. 1) .
Measurement of IK1 by Whole-Cell Patch Clamp
Patch pipettes were prepared by pulling borosilicate glass capillaries (Hilgenberg, Malsfeld, Germany). The pipette solution contained (in mmol/l) 140 K aspartate, 5 MgCl2, 5 K2ATP, 5 EDTA, and 5 HEPES (pH 7.2). Patch pipettes had a resistance of 2-4 MΩ when filled with the pipette solution. After rupture of the cell membrane, whole-cell membrane currents were recorded at room temperature using ramp or square pulses. Ramp clamping was performed with a functional generator (FG-122; NF Corporation, Yokohama, Japan) with a pulse range between −120 and 0 mV and a holding potential of −40 mV. The ramp pulses of 1.5 V/s were applied every 3 s as shown in the inset of Fig. 2A . We also used voltage steps ranging from −120 to 0 mV in 10 mV increments from a holding potential of −40 mV (Fig. 2D) .
The test pulse duration was 300 ms and the test voltage steps were delivered every 5 s. The membrane potential was not corrected for the liquid junction potential, which was estimated to be < 10 mV. Data were acquired and analyzed using a personal computer (PC98XL; NEC, Tsukuba, Japan) equipped with an analog/digital converter (PCM-DP16; SHOSHIN EM Corporation, Okazaki, Japan). IK1 was defined as a Ba 2+ -sensitive current obtained by subtracting the current measured in the presence of 3 mmol/l Ba 2+ (c in Fig. 2B ) from the total current measured in the absence of Ba 2+ (a in Fig. 2B ) (20) . The slope conductance of IK1 was calculated from the linear region of the current-voltage (I-V) curves. We focused on the inward portion of the Ba 2+ -sensitive currents, because the outward portion may also include other K + currents, such as delayed-rectifier K + currents and transient outward currents (21) .
Measurement of Single IK1 Channel Currents
Single IK1 channel currents were recorded in both cellattached and inside-out patch configurations. For the cellattached patch, the experimental chamber was continuously perfused (1-2 ml/min) with Tyrode's solution. Superfusion with high K + solution depolarized the membrane potential so that it was maintained at a holding potential of −80 mV by performing the voltage clamp, creating the inside-out patch mode. For the inside-out patch, the bath solution contained (in mmol/l) 120 K aspartate, 25 KCl, 3 Na2ATP, 5 EGTA, 5 HEPES and 1 MgCl2 (pH 7.2) and the pipette solution contained 145 KCl and 5 HEPES (pH 7.4). Signals were filtered off-line with a cut-off frequency of 2 kHz through an eightpole low-pass Bessel filter (48 dB/octave, model 902-LPF; Frequency Devices, Inc., Haverhill, USA), digitized with 14-bit resolution at a sampling rate of 10 kHz, and stored on an LSI 11/73 computer (Digital Equipment Corporation, Maynard, USA).
Intracellular Ca 2+ Concentration Measurement
The intracellular Ca 2+ concentration ([Ca 2+ ]i) was measured using Indo-1 and a dual wavelength spectrophotometric method (22) . Cells were loaded with 3 μmol/l Indo-1 acetoxymethyl ester (Molecular Probes, Inc., Eugene, USA) for 20 min at 37°C. The Indo-1-loaded cells were placed in the recording chamber and superfused with Tyrode's solution. Fluorescence (at > 500 nm) from sequential illumination (408 and 485 nm) at 0.3 Hz was measured using a spinning wheel spectrophotometer (Cairn Research, Ltd., Faversham, UK).
Data Analysis
The concentration-dependence of the Ang II−induced decrease in the slope conductance of IK1 was fitted to the following equation:
where 
Measurement of cAMP
Cells were incubated in Kraftbruhe (KB) buffer containing (in mmol/l) 115.9 KOH, 80 glutamic acid, 10 taurine, 14 oxalic acid, 10 KH2PO4, 10 HEPES, 25 KCl, 11 glucose and 0.5 EGTA (pH 7.4), with or without Ang II (100 nmol/l) at 37°C for 30 min. The reaction was terminated by the addition of 6% (v/v) trichloroacetic acid. The extracts were centrifuged at 3,000 rpm for 15 min and cAMP contents in the supernatants were determined by using an Eiken cAMP Kit (Eiken Kagaku Co., Tokyo, Japan).
Immunoblot
The atrium was homogenized with a polytron in the buffer (PBS supplemented with 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml pepstain and 1 mmol/l phenylmethylsulfonylfluoride), and insoluble materials were removed by centrifugation.
Immunoprecipitation with anti-human AT1 (23-26) (sc-1173AC; Santa Cruz Biotechnology, Santa Cruz, USA) was carried out in PBS/1% Triton X-100, 0.5% SDS, 0.25% sodium deoxycholate, 1 mmol/l EDTA, and protease inhibitors for 2 h at 4°C. The immunocomplexes were collected with protein G-agarose (Pharmacia, Piscataway, USA), separated on 7.5% SDS-polyacrylamide gels under a reducing condition including β-mercaptoethanol, and electrotransferred to a nitrocellulose membrane. Membranes were probed with antibodies against Gi-2α (NeoMarkers, Fremont, USA) or Gi-3α (Santa Cruz Biotechnology). They were developed by using an enzymatic chemiluminescence (ECL) detection system (Amersham International, Buckinghamshire, UK). 
Drugs
Statistical Analysis
Two-way ANOVA test and Fisher's exact test for post hoc analysis were carried out for multiple comparisons among groups. All data are derived from more than 4 experiments and expressed as the mean±SEM, with values of p< 0.05 being considered statistically significant.
Cell Transfection
An expression construct pcDNA3.1/rat AT1 was used for transfection experiments (28) . COS7 cells were maintained in Dulbecco's modified Eagle's medium (Gibco BRL, Gaithersburg, USA)/10% fetal bovine serum at 37°C in a 5% CO2 incubator. Cells were transfected by using lipofectamine (Gibco BRL) according to the manufacturer's instructions. Forty-eight hours after transfection, the cell extracts were prepared for immunoblotting using the same extraction buffer as used for immunoprecipitation.
Results
Predominant Expression of AT1 in the Rat Atrium
Ang II receptor densities were assessed by [
125 I]-SarIle-Ang II-binding assays using membrane preparations from rat atria. When non-specific binding was defined with excess cold Ang II, Scatchard analysis of the saturation data revealed a linear blot with Kd values of 1.30±0.04 nmol/l and maximum-binding capacities of 7.8±0.3 fmol/mg protein (means±SD, n=13) (Fig. 1A) . Inhibition isotherms with the AT1-selective antagonist losartan gave a biphasic curve (Fig.  1B) . Nonlinear least-square regression analysis suggested the presence of AT1 and AT2 with 50% inhibitory concentration (Ki) values of 15 nmol/l and 89 μmol/l for losartan. The relative binding capacities for the two subtypes were estimated to be 9:1. The same analysis with the AT2-antagonist CGP4112A again showed the presence of both AT1 and AT2, with Ki values of 0.5 μmol/l and 0.4 nmol/l for CGP42112A (Fig. 1C) . In good agreement with the results using losartan, the relative binding capacities were estimated to be 9:1.
Scatchard analysis of the data from SHR membrane prepa- (Fig. 1A) . Inhibition isotherms with losartan and nonlinear least-square regression analysis suggested the presence of AT1 and AT2, with Ki values of 23 nmol/l and 66 μmol/l for losartan, and the relative binding capacities of 8:2 (Fig. 1B) . The same analysis with CGP42112A again showed the presence of both AT1 and AT2, with Ki values of 1.1 μmol/l and 0.8 nmol/l and relative binding capacities of 8:2 (Fig. 1C) . These data suggested that the relative binding capacities of the two receptor subtypes were not altered, but the densities of both receptors were increased approximately two-fold in SHR atrial membrane preparations as compared with controls.
Fig. 1. [ 125 I]-SarIle-Ang II binding to atrial membranes. A: Scatchard plots of the specific [ 125 I]-SarIle-Ang II binding to atrial membranes of WKY (open circles) and SHR (closed circles). B: Inhibition by losartan. C: Inhibition by
Inhibition of IK1 by Ang II in Rat Atrial Myocytes
Ang II (100 nmol/l) reduced the amplitude of both inward and outward portions of the steady-state currents elicited by ramp pulses (a-b in Fig. 2A, B) . The amplitude was restored following withdrawal of Ang II (b-c in Fig. 2A ). Neither cadmium (100 μmol/l) nor tetrodotoxin (10 μmol/l) affected the Ang II-induced changes in the slope conductance, excluding an involvement of voltage-gated Ca 2+ or Na + channels. The I-V curves showed that Ang II reduced the steady-state current over the whole potential range (a-b in Fig. 2B ) and the subse- Fig. 2B) . Subtraction of the Ba 2+ -insensitive fraction indicated that Ang II (100 nmol/l) reduced inward IK1 by 40% at −120 mV and outward IK1 by 44% at 0 mV (a-c to b-c in Fig. 2C ). Similar effects of Ang II were obtained using voltage step pulses: Ang II (100 nmol/l) reduced inward IK1 by 40% at −120 mV and outward IK1 by 40% at −40 mV (Fig. 2D) . The reduction of the IK1 slope conductance by Ang II was concentration-dependent (29) with an IC50 of 46 nmol/l and a Hill coefficient of 1.1, and the effect was saturated at concentrations higher than 1 μmol/l (Fig. 3A) .
To determine the receptor subtype responsible for the Ang II effects, we used the AT1 antagonist RNH6270 and the AT2 antagonist PD123319. The inhibition of IK1 by Ang II was abolished by RNH6270 but not at all by PD123319, indicating that AT1 is responsible for the inhibition of IK1.
To determine G protein subtypes coupled with AT1 in these cells, we examined the effects of Ang II on the cAMP concentration and [Ca 2+ ]i. Ang II (100 nmol/l) reduced cAMP contents by 65%, and this effect was abolished by pretreatment of the cells with PTX (Fig. 3B) . This inhibition was also abolished by RNH6270 (data not shown). Ang II (100 nmol/l) caused a transient increase in [Ca 2+ ]i, which was completely (Fig. 3C ). This effect on [Ca 2+ ]i was also abolished by RNH6270 (data not shown). These data indicated that AT1 coupled with the Giα and Gqα proteins in these cells.
Fig. 3. Effects of various agents on the Ang II-induced changes in atrial IK1, cAMP production and [Ca 2+ ]i in rat atrial myocytes. The concentration of Ang II was 100 nmol/l. A: Effects of AT1 and AT2 blockers. The ordinate indicates the % conductance of IK1 normalized to the control (100%). Each bar represents the mean±SEM of more than 5 experiments. B: Effect of Ang II on cAMP production. Each bar represents the mean±SEM of more than 5 experiments. C: Effect of Ang II on [Ca 2+ ]i. [Ca 2+ ]i was measured at the electrically stimulated state (open circles) or the unstimulated state (closed circles) with or without Ang II. In separate sets of cells, U-73122 (0.6 μmol/l) was added before application of Ang II. D: Effects of various agents on inhibition of IK1 by Ang II (slope conductance at −120 mV). Each bar represents the mean±SEM of more than 5 experiments. *p< 0.05.
To determine the G protein subtype responsible for inhibition of IK1, we examined the effects of PTX and an EC-blocking peptide against Giα-3 proteins and U-73122. The Ang II effect was abolished when cells were pretreated with PTX or the EC peptide, indicating the involvement of PTX-sensitive Giα proteins. In contrast, U-73122 failed to effect the blocking of IK1 by Ang II (Fig. 3D) . To confirm the role of cAMP/ PKA, we tested whether forskolin or dibutyryl-cAMP could counteract Ang II and found that both drugs abolished the Ang II effects. Neither isoproterenol, forskolin or dibutyrylcAMP (data not shown), when applied alone, affected the slope conductance of IK1. Taken together, these results indicate that Giα, but not Gqα, is responsible for the inhibition of IK1.
To characterize the mode of action of Ang II, we performed single channel recordings using cell-attached and inside-out patches. In the cell-attached patch, extracellular Ang II (100 nmol/l) reduced IK1 channel activities (Fig. 4A , before air exposure), by increasing interburst intervals but not unit amplitudes (Fig. 4B, left and middle) . The single channel conductances before and during administration of Ang II were 35±3 pS and 33 ±6 pS, respectively, which were consistent with the characteristics of IK1 (20) . In the inside-out patch, Ang II inhibited the IK1 channel activities and the activities were restored by application of PKA catalytic subunits on the intracellular side (10 U/ml) (Fig. 4A , after air exposure and Fig. 4B , middle and right). This was consistent with the finding in the whole cell clamp that the bath application of dibutyryl-cAMP restored the IK1 (data not shown).
Lack of Ang II Effects on IK1 in Cells from SHR
Given the previous report on alterations of IK1 in ventricular myocytes isolated from SHR (14), we compared IK1 between cells from control rats and SHR. We found little difference either in the inward or outward portions of the steady-state currents: as shown in Fig. 5A , the slope conductance of IK1 (inward portion at −120 mV) in cells from SHR (15.0±4.9 nS) was close to that in cells from normal rats (11.1± 5.2 nS).
In spite of the increased binding capacities for [ 125 I]Ang II in the atrial membrane preparations (Fig. 1) , Ang II (100 nmol/l) failed to inhibit IK1 in cells from SHR (Fig. 5A, B) . Ang II failed to decrease cAMP contents in SHR cells (Fig.  5C) , suggesting an impaired signal transduction from AT1 to AC. These findings were reproduced in the presence of PD123319, indicating the negative contribution of AT2 (data not shown). We then examined the protein levels of Gi proteins in SHR atrial extracts by Western blotting and their association with AT1 by immunoprecipitation. There were no significant differences in the expression levels of AT1, Gi-2α and Gi-3α proteins in the extracts between control and SHR extracts (Fig. 6A, B) , although the ventricular AT1 expressions in SHR were higher than those in WKY rats (Fig. 6A) , indicating the left ventricular remodeling of SHR.
AT1 immunoprecipitation, however, showed that the amounts of Gi-2α and Gi-3α proteins associated with this receptor were reduced in SHR (Fig. 6C) . The data obtained from the 6 different experiments indicated that the fraction of densities of immunoprecipitated Gi-2α and Gi-3α proteins with this receptor were significantly reduced in the atrium of SHR (to 52±12% and 54 ±9%, respectively, of the levels in normal rats, Fig. 6D ).
Discussion
We found that in rat atrial myocytes, Ang II inhibited IK1 and that this inhibition was due to activation of AT1 coupled with PTX-sensitive Gi proteins. The finding that the effects of Ang II were suppressed by forskolin, dibutyl-cAMP and the PKA catalytic subunit argues that the decreased cAMP levels and hence the decreased PKA activity resulted in inhibition of IK1. Neither isoproterenol, forskolin or dibutyl-cAMP affected IK1, indicating that the channel activity did not respond to an increase in the cAMP/PKA activity. One possible explanation for this lack of response is that the channels may be fully phosphorylated by PKA at the steady state: in this case, the increase in PKA activity would not cause any increase in the phosphorylation of the channels, whereas the decrease in the activity could result in reduced phosphorylation. Direct assessment of the phosphorylation state of the channel proteins is required to test this assumption. As for the regulation of IK1 by PKA, our findings are contradictory to a previous report by Koumi et al. (11) , who found that PKA activation decreased IK1 in guinea-pig ventricular myocytes. This discrepancy is most likely explained by the differences in the molecular nature of the channel proteins, and thus further studies will be needed to characterize the channel proteins responsible for IK1 in individual cell types.
Our findings are also contradictory to those of Morita et al. (8) , who found that Ang II increased IK1 in rabbit ventricular cells. This discrepancy may be due either to species/tissueselective activation of signaling pathways or to the differential nature of the channel proteins themselves. Preliminary results from our laboratory showed that the amounts of Gi proteins co-precipitated with AT1 were considerably less in rat ventricular extracts than in atrial extracts in both WKY rats and SHR (data not shown), suggesting tissue-selective activation of AT1/Gi signaling pathways by Ang II.
We could not see any differences in the electrophysiological characteristics of atrial IK1 between normotensive rats and SHR, in contrast to the observation by Li and Jiang (15) , who found that the inward portion of ventricular IK1 was significantly smaller in SHR than that in normotensive rats. Although there was not any significant difference of IK1 between SHR and WKY rats in the present study, the message level among the two strains might be different. Since in general the channel level is determined by not only the transcriptional level but also the posttranslational modification, it remains possible that the increases in mRNA of the atrial IK1 in SHR could be canceled by the excess degradation of IK1 channel proteins. Neither could we detect any differences in the expression levels of Gi proteins in atrial extracts, in contrast to the observation by Thibault and Anand-Srivastava (31), who found an increased expression of Gi-α proteins in the ventricles of SHR compared with normotensive rats. Although the precise reason for these discrepancies remains uncertain, they may reflect differential responses to chronic hypertension between atrial and ventricular myocytes.
There was a discrepancy between [ 125 I]-SarIle-Ang II-binding capacities and the protein levels in the Western blot analysis. Although the precise reason for this discrepancy remains uncertain, this phenomenon is not specific to AT1 (32) . Similar discrepancies between ligand-binding capacities and protein levels detected with anti-receptor antibodies have been described for various GPCRs, such as endothelin receptor type A (33), platelet-activation factor receptors (34) and opioid receptors (35) . Recently, it has been reported that alternative splicing of AT1 results in differential protein levels (36) . Since the protein levels of AT1 were unaltered on the Western blot, it is unlikely that the alternative splicing resulted in the difference in binding capacities. Alternatively, the difference of Ang II-binding capacities and AT1 expression in the atrium of SHR might be explained by an increase in the affinity of AT1 to compensate for the uncoupling of AT1 to Gi, which should be a subject for future study.
Despite the increase in the [ 125 I]Ang II-binding capacities and the unaltered expression levels of Gi proteins, Ang II failed to activate Gi proteins or to inhibit IK1 in SHR atrial cells. Results from AT1 immunoprecipitation experiments suggested that this failure was due to uncoupling of AT1 with Gi proteins. The activation of AT1 produces oxidative stress (37, 38) . The coupling state of signaling proteins can be altered in SHR. For example, it has been reported that the elevated oxidative stress in SHR induced uncoupling of the dopamine receptor from the Gi protein in renal proximal tubules (39) . We also confirmed that ventricular AT1 was increased in SHR in the present study, indicating that the SHR underwent left ventricular remodeling. Therefore, this coupling status may be at least partly the consequence of hypertensive cardiac remodeling involving oxidative stress, although we did not measure the oxidative stress in the atrium in the present study.
However, it remains possible that it is a phenomenon specific to the SHR strain. Therefore, the effect of the hypertensive state on the heart should be tested using another animal model, such as Dahl rats with or without salt loading. The precise mechanism responsible for this uncoupling of receptors from G protein is a worthy subject for future study.
The plasma concentration of Ang II is between 5 and 50 pmol/l in humans (40) , while in the present study Ang II effectively inhibited IK1 with IC50 values of 46 nmol/l. Ang II secretion from podocytes is elevated in various disease states with increased mechanical stress (41) and the tissue concentrations of Ang II, such as in the skeletal muscle and heart, can be higher than those in plasma (42) , suggesting that the level of local Ang II might not be very different from the concentration used in the present study. The finding that a higher concentration of Ang II was required to block IK1 casts doubt on the physiological relevance of the action of Ang II. However, most studies estimating the effects of Ang II on the ion channels have been conducted within the concentration range of 1-100 nmol/l, and thus the concentrations of Ang II used in the present study can be considered acceptable for electrophysiological experiments.
Previous experimental and clinical studies (43) (44) (45) (46) (47) have reported that activation of the atrial renin-angiotensin system may contribute to the occurrence of atrial arrhythmias. Hypertension is the most common cardiovascular antecedent cause of atrial fibrillation (45) . Goette et al. (44) have reported that the activation of AT1 receptor in the atrium could promote Ang II-dependent progressive atrial fibrosis. Nakashima et al. (45) have demonstrated in the canine atrium that AT1 blockers prevent shortening of the effective refractory period during high rate pacing, suggesting that the activation of the AT1 receptor would shorten the atrial action potential duration (APD), which in turn causes atrial arrhythmias. We recently reported that Ang II prolonged the atrial action potential duration in WKY rats (48) , indicating its antiarrythmic action on the atrium; however, in another study Ang II shortened the atrial action potential duration in SHR (49) , indicating its proarrhythmic action on the atrium in hypertensives. Thus, reduction of IK1 could lead to prolongation of the action potential duration, which may underlie the antiarrhythmic action of Ang II in normotensive rats (20) . In SHR, the lack of IK1 inhibition by Ang II may lead to attenuation of its antiarrythmic action. There may be a link between the lack of IK1 inhibition by Ang II in SHR and the incidence of arrythmias in human hypertensive patients.
